This content is from: Premium
How RA Capital Cashes in on Private Deals
The little known life sciences hedge fund firm is a major investor in Covid-19 vaccine developer Novavax.
Shares of Novavax are on the move again.The biotechnology company and vaccine developer, whose Covid-19 vaccine candidate is in various clinical trials and is being tested in South Africa and the U.K., was up nearly 7 percent on Monday, closing at $221.50. The stock also is up nearly 30 percent in
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.